A patient with focal epilepsy poorly controlled on carbamazepine is found to be a CYP3A4 ultrarapid inducer due to genetic variation. The MOST pharmacologically accurate explanation for therapeutic failure is:
- A CYP3A4 ultrarapid inducers express P-glycoprotein overactivity, effluxing carbamazepine at the blood-brain barrier
- B CYP3A4 ultrarapid inducers convert carbamazepine exclusively to carbamazepine-10,11-epoxide which has no anticonvulsant activity
- C Carbamazepine autoinduces its own CYP3A4-mediated metabolism; ultra-induction genotype amplifies autoinduction, dramatically reducing carbamazepine plasma levels ✓
- D The ultrarapid CYP3A4 genotype hydroxylates carbamazepine to a nephrotoxic metabolite causing renal clearance to fall
Explanation
Carbamazepine is a potent inducer of CYP3A4 (the enzyme primarily responsible for its own metabolism) — a phenomenon termed autoinduction. After starting therapy, carbamazepine progressively accelerates its own metabolism over 3–5 weeks, halving its initial half-life from ~35 h to ~15 h. In a patient with a genetic ultrarapid CYP3A4 phenotype, this autoinduction is exaggerated, resulting in sub-therapeutic plasma concentrations despite adequate doses. The active metabolite carbamazepine-10,11-epoxide does retain anticonvulsant activity and is not the cause of failure. P-glycoprotein overexpression is a separate (acquired) mechanism of drug-resistant epilepsy.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.